Non classé | Eukarys

Eukarÿs appoints Nicole Faust and Bryan Poltilove as strategic advisors

Pixmaker — Sat, 01 Nov 2025 09:36:36 +0000

After having mentored Eukarÿs during the Biotools Innovator acceleration program, Nicole Faust and Bryan Poltilove join the company as strategic advisors.

As former CSO and CEO of CEVEC (acquired in 2024 by Cytiva, Danaher group), a world first technology cell line company, Nicole brings both her technical capabilities in cell line engineering and her successful experience in building a leader of the biomanufacturing technology.

As former VP/GM with Thermo Fisher and Operating Partner with BroadOak Capital, Bryan brings a rare combination of experience in business leadership, strategy, and investing in the field of biomanufacturing technology.

Eukarÿs strengthens its Board of Directors by appointing Eric Drape, world recognized expert of the biomanufacturing industry

Pixmaker — Sun, 01 Jun 2025 08:32:13 +0000

One year after the appointment of Gabriel Festocand Anne Lauvergeon as board members, Eukarÿs is pleased to announce a new step in the strengthening of its Board of Directors with the appointment of Eric Drapé.

As former EVP Operations of TEVA, Eric brings a deep knowledge of the biomanufacturing industry. Being board member of Lonza and of LFB, Eric also brings his rare experience in corporate governance in the biopharma and biomanufacturing field.

Genethon and Eukarÿs announce strategic partnership to develop breakthrough technology for lowering the biomanufacturing cost of biomanufacturing gene therapies

Pixmaker — Thu, 23 Jan 2025 08:00:00 +0000

Eukarÿs and Genethon have announced a strategic partnership to reduce the cost of gene therapy drugs production. By combining Eukarÿs’ innovative disruptive C3P3 technology, which enhances unleashes mRNA synthesis in mammalian cells, with Genethon’s expertise in AAV vector production, the partnership aims to significantly increase production yields, leading to more affordable and accessible gene therapies. Eukarÿs’ C3P3 enzyme can multiply the production yields of all other biomedicines by a factor of 5 to 7. Without requiring any adaptation or investment in new equipment, nor any changes toin existing industrial processes, thus changing the game improving the efficiency of biomanufacturing in biomedicines manufacturing. This collaboration will help accelerate the development of cost-effective gene therapies for patients in need, and contribute to make them accessible to a wider part of the global population.

Access the full Press Release FR/ EN:

French English

Eukarÿs strengthens Board of Directors with new appointments

Pixmaker — Tue, 16 Apr 2024 13:30:00 +0000

Eukarÿs is pleased to announce the strengthening of its Board of Directors alongside the appointment of Guillaume Prunier as CEO. Gabriel Festoc, PhD, former President of Polyplus (acquired by Sartorius in 2023 for €2.4 billion), is a leading expert in bioproduction technologies, particularly in cell & gene therapy. Anne Lauvergeon, representing ALP, brings her industrial and financial expertise. Formerly Managing Partner at Lazard and CEO of Areva, she is a strong advocate of innovation. These strategic appointments will help Eukarÿs leverage its cutting-edge C3P3® technology to revolutionize the biomanufacturing industry.

Publication: Progress in mRNA stabilization

Pixmaker — Sat, 02 Mar 2024 14:33:00 +0000

We are pleased to announce the publication of Eukarÿs’ latest research in Nature – Scientific Reports.

The paper, entitled « Rational Design of an Artificial Tethered Enzyme for Non-Templated Post-Transcriptional mRNA Polyadenylation by the Second Generation of the C3P3 System », introduces the G2 module of the C3P3 enzyme, a significant advancement that enhances the stabilization of mRNA produced by the C3P3 system, thanks to a polyadenylation process.

This breakthrough is part of an international patent family and marks a new phase in the capabilities of the C3P3 enzyme for biotechnology applications. The functionality of the G2 module allows for improved stabilization of mRNA, paving the way for enhanced mRNA-based research and therapeutic opportunities. This positions Eukarÿs at the forefront of innovative scientific solutions to drive the future of mRNA technologies.

Guillaume Prunier appointed CEO of Eukarÿs

Pixmaker — Fri, 01 Mar 2024 14:26:00 +0000

Eukarÿs is pleased to announce the appointment of Guillaume Prunier as its new Chief Executive Officer, effective March 1st 2024. A serial entrepreneur with expertise in DeepTech innovation, Guillaume previously served as CEO of Flaminem, a big data and AI startup that he successfully made pivot, and was since acquired. He also served as deputy CEO of Inria, France’s national research institute for computer sciences and technologies, and as special advisor to the president of Eukarÿs from 2020. Guillaume holds degrees from École Polytechnique and Mines ParisTech. With his wealth of experience, Guillaume will guide Eukarÿs through its next phase of growth, using the company’s cutting-edge C3P3® technology to transform biomanufacturing.

Patent Family #3: Increasing the Efficiency of the C3P3 Enzyme

Pixmaker — Tue, 03 Aug 2021 13:39:00 +0000

The third patent family builds on the previous two and provides a highly significant boost to the efficacy of the C3P3 enzyme. Filed in 2021, it protects the innovative concept of C3P3-G3, which inhibits the critical phosphorylation of subunit A of the translation initiation factor eIF2 (eIF2a) in cells expressing mRNA synthesized by the C3P3 enzyme. By inhibiting a cellular defense mechanism against mRNA produced by the C3P3 enzyme, the G3 module complements the structure of the enzyme and dramatically improves its overall efficiency.

Eukarÿs wins the 2019 US Prix Galien MedStartUp award

Pixmaker — Thu, 24 Oct 2019 13:42:35 +0000

Eukarÿs is proud to announce that it has won the prestigious US Prix Galien MedStartUp 2019 for ‘Best collaboration with the pharmaceutical or biotechnology industry’. The award was presented on October 24 at the Alexandria Life Sciences Center in New York. The award recognizes Eukarÿs’ partnership with Dr. Maya Shmulevitz’s Molecular Virology and Oncology Laboratory at the University of Alberta. Together they developed the C3P3 system for viral bioproduction, focusing on oncolytic reoviruses for cancer therapy. The prize jury, chaired by Bernard Poussot (Chairman of Roche Holding), included senior executives from Sanofi, GSK, Pfizer, Johnson & Johnson, UCB and Evercore Partners. This achievement underscores Eukarÿs’ commitment to advancing human health through innovation.